《大行》野村升石藥集團(01093.HK)目標價至10.22元 評級「買入」
野村發表報告,對石藥集團(01093.HK)目標價由8.02元升至10.22元,評級「買入」。石藥集團與阿斯利康訂立戰略研發合作協議,利用石藥的AI引擎雙輪驅動的高效藥物發現平台,發現和開發新型口服小分子候選藥物。根據協議,石藥將獲得1.1億美元的預付款,並有資格獲得最高16.2億美元的開發里程碑付款、最高36億美元的銷售里程碑付款,以及基於產品年度淨銷售額的個位數百分比銷售提成。這是繼2024年10月石藥與阿斯利康的上一項許可協議後的又一合作。
報告指,該交易短期內通過預付款增強石藥的財務狀況,長期則體現其AI驅動的研發能力。若里程碑和版稅順利實現,未來可能帶來顯著收入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.